Abstract
Imiquimod is a synthetic imidazoquinolin heterocyclic amine of 240.3 Da (C14H16N4). Imiquimod is a cytokine inducer and a modifier of the innate immune response that can enhance acquired antiviral and anti-tumor immune responses. Imiquimod cream 5% is a treatment approved for external genital warts, superficial basal cell carcinoma and actinic keratosis. Imiquimod cream 5% has also been evaluated in the treatment of molluscum contagiosum, cutaneous leishmaniasis, nodular basal cell carcinoma, Bowen’s disease, anogenital intraepithelial neoplasia and skin dysplasia in transplant recipients in randomized controlled trials. Several case series’ have also reported the use of imiquimod cream 5% in many other skin conditions, such as common warts, melanoma in situ, T-cell cutaneous lymphoma, extramammary Paget’s disease, hemangioma and prevention of keloids after surgery.
Financial & competing interests disclosure
D Vidal has acted as a paid speaker to 3M Pharmaceuticals and A Alomar has acted as a paid speaker, investigator and consultant to 3M Pharmaceuticals. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
